Table 1.
Antibiotic minimum inhibitory concentrations (mg l–1) of isolates in this study
|
Isolate |
Collection date (MM/YY) |
Ciprofloxacin |
Meropenem |
Tobramycin |
Ceftazidime |
|---|---|---|---|---|---|
|
E-S2239-16 |
12/91 |
0.5 |
0.25 |
0.25 |
1 |
|
E-MSB2494 |
12/91 |
1* |
0.25 |
0.25 |
1 |
|
E-MSB3405 |
12/91 |
1 |
0.125 |
0.25 |
0.5 |
|
E-S2239-15 |
12/91 |
1 |
1 |
2 |
1 |
|
L-001–1A |
08/12 |
2 |
16 |
8 |
4 |
|
L-001-1B |
08/12 |
4 |
16 |
2 |
16 |
|
L-001–1C |
08/12 |
2 |
8 |
8 |
4 |
|
L-001–2A |
10/12 |
2 |
8 |
8 |
8 |
|
L-001-2B |
10/12 |
2 |
8 |
8 |
4 |
|
L-001–3A |
11/12 |
2 |
8 |
4 |
4 |
|
L-001-3B |
11/12 |
2 |
8 |
2 |
4 |
|
L-001–4 |
01/13 |
2 |
8 |
2 |
4 |
|
L-001–5A |
04/13 |
1 |
16 |
4 |
4 |
|
L-001-5B |
04/13 |
2 |
8 |
2 |
16 |
|
L-001–6 |
05/13 |
2 |
16 |
2 |
8 |
*Antibiotic resistance is shown in bold type. Resistance breakpoints (eucast.org) are: ciprofloxacin, >0.5; meropenem, >8; tobramycin, >2, ceftazidime, >8.